Global Intravitreal (IVT) Injectables Market Size By Type (Anti-VEGF, Corticosteroids), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Intravitreal (IVT) Injectables Market was valued at USD 5.9 billion in 2023 and is projected to reach USD 11.7 billion by 2031, growing at a CAGR of 8.9% during the forecast period from 2023 to 2031. Intravitreal injectables have become critical in the treatment of various retinal disorders such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The growing prevalence of these conditions, coupled with the rise in the aging population, is significantly fueling the demand for IVT therapies. Additionally, advancements in biologics and extended-release drug delivery systems are enhancing treatment efficacy and patient compliance, contributing to sustained market growth.

Drivers:

1. Rising Prevalence of Retinal Disorders:

The global increase in diabetic patients and an aging population has led to a higher incidence of retinal diseases like diabetic macular edema (DME) and wet AMD, driving demand for IVT injectables.

2. Technological Innovations in Drug Delivery:

The development of sustained-release and biodegradable intravitreal implants is reducing injection frequency, improving patient adherence, and expanding treatment options.

3. Increasing Regulatory Approvals:

Growing R&D activities and regulatory support have led to the approval of innovative IVT therapies, bolstering the market pipeline and facilitating faster patient access.

Restraints:

1. High Cost of Treatment:

The cost of repeated injections, especially anti-VEGF drugs, imposes a significant financial burden on patients, particularly in low- and middle-income countries.

2. Risks Associated with Repeated Injections:

Complications such as endophthalmitis, retinal detachment, and increased intraocular pressure can arise with frequent IVT injections, limiting patient willingness and clinical use.

Opportunity:

1. Emerging Markets Expansion:

Growing investments in healthcare infrastructure and rising awareness in countries across Asia-Pacific, Latin America, and the Middle East & Africa are creating new opportunities for IVT therapies.

2. Pipeline of Long-Acting Therapies:

The development of next-generation intravitreal formulations with extended dosing intervals could revolutionize treatment regimens, reduce burden on healthcare systems, and improve patient outcomes.

Market by System Type Insights:

Based on system type, the Anti-VEGF Segment held the largest share in 2023 and is projected to maintain dominance through 2031. Anti-VEGF agents such as ranibizumab, aflibercept, and brolucizumab have become the standard treatment for wet AMD and DME due to their proven efficacy and safety profiles. Meanwhile, the Corticosteroids Segment is expected to witness notable growth, particularly for patients with corticosteroid-responsive disease or anti-VEGF resistance.

Market by End-use Insights:

The Hospitals Segment accounted for the largest market share in 2023. Hospitals remain the primary setting for IVT injections due to the need for sterile environments, skilled ophthalmologists, and access to follow-up care. However, the Ambulatory Surgical Centers (ASCs) segment is expected to grow rapidly due to cost-effectiveness, quicker turnaround times, and rising adoption of outpatient IVT administration.

Market by Regional Insights:

North America led the global intravitreal injectables market in 2023, driven by a high prevalence of AMD and diabetes, favorable reimbursement policies, and advanced healthcare infrastructure. Asia-Pacific is forecast to be the fastest-growing region during the forecast period, fueled by rising healthcare expenditure, increasing awareness about eye health, and expanding access to ophthalmic care in emerging economies like China and India.

Competitive Scenario:

Key players in the global intravitreal injectables market include Roche (Genentech), Regeneron Pharmaceuticals, Novartis AG, Bayer AG, Allergan (AbbVie), Bausch + Lomb, Alimera Sciences, Kodiak Sciences, and Ocugen Inc. These companies are actively investing in R&D, expanding their product pipelines, and exploring strategic collaborations.

Key Market Developments:

In 2023, Roche received FDA approval for Vabysmo (faricimab), a dual-pathway IVT injection, offering longer dosing intervals for AMD and DME.

In 2024, Kodiak Sciences advanced its KSI-301 into late-stage clinical trials, targeting long-acting efficacy in retinal disease treatment.

In 2025, Novartis partnered with a digital health firm to enhance patient monitoring and adherence to IVT treatment protocols.

Scope of Work – Global Intravitreal (IVT) Injectables Market

Report Metric Details

Market Size (2023) USD 5.9 billion

Projected Market Size (2031) USD 11.7 billion

CAGR (2023–2031) 8.9%

Market Segments By System Type (Anti-VEGF, Corticosteroids, Antibiotics/Antifungals), By End-use (Hospitals, ASCs, Others), By Region

Growth Drivers Rising prevalence of retinal diseases, technological innovation in drug delivery, favorable regulatory landscape

Opportunities Growth in emerging markets, introduction of long-acting therapies

FAQs:

1) What is the current market size of the Global Intravitreal (IVT) Injectables Market?

The market was valued at USD 5.9 billion in 2023.

2) What is the major growth driver of the Global Intravitreal (IVT) Injectables Market?

The major growth driver is the increasing prevalence of retinal diseases such as AMD and diabetic retinopathy.

3) Which is the largest region during the forecast period in the Global Intravitreal (IVT) Injectables Market?

North America is projected to remain the largest regional market during the forecast period.

4) Which segment accounted for the largest market share in the Global Intravitreal (IVT) Injectables Market?

The Anti-VEGF segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Intravitreal (IVT) Injectables Market?

Key players include Roche, Regeneron, Novartis, Bayer, AbbVie (Allergan), Bausch + Lomb, and Kodiak Sciences.